Our Psychedelic Trip Isn’t Over I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector…
Psychedelic
A Transformative Year $18.123M Market Capitalization Filament Health Corp. (FH.NE) today released its Q4 2021 financial results and has provided operational highlights for the period ended December 31, 2021….
Two for Two $23.066M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a second patent by the Canadian Intellectual Property Office (CIPO) for the…
Standardizing Psychedelic-Assisted Therapy $25.537M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has entered into a licensing agreement with ATMA Journey Centers. Under the agreement, Filament has…
A Change In Stance Filament Health Corp (FH.NE) announced today that Psilo Scientific Ltd., the Company’s wholly-owned subsidiary, has joined Health Canada’s list of licensed psilocybin producers. No, we…
Not So Generalized Disorder “Anxiety is a part of normal life.” Or so I was told. Whether I was simply leaving my apartment to get food or speaking during…
Filament Health Corp. (FH.NE) announced today that it has entered into a co-development and exclusive licensing agreement with EntheoTech Bioscience Inc. “Our partnership with EntheoTech showcases our commitment to…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Mindset Pharma (MSET.C) announced they have filed a new patent with the US Patent and Trade Office (USPTO), extending its Family 4 compounds, a set of novel DMT/5-MeO-DMT analogs….
Mydecine Innovations Group (MYCO.NE) announced they have signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine. The research will be led by Dr. Matthew Johnson…